Stephen V Liu: Real-world study of first-line nivolumab and ipilimumab for pleural mesothelioma

Stephen V Liu shared a post on X, about recent paper published in Clinical Lung Cancer:

Efficacy of First-Line Nivolumab plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM).

Authors: Diego Enrico, Juan Elias Gomez, Danilo Aguirre, Natalia Soledad Tissera, Florencia Tsou, Carmen Pupareli, Delfina Peralta Tanco, Federico Waisberg, Andrés Rodriguez, Manglio Rizzo, Nicolas Minatta, Picon Rafael, Luis Basbus, Lorena Lupinacci, Diego Kaen, Mauro Ramos, Virginia Bluthgen, Nicolas Castagneris, Maria Pia Coppola, Alejandra Scocimarro, Maria Florencia Guerra, Aldo Perfetti, Patricio Levit, Marco Galvez-Nino, Luis Mas, Leonardo Rojas, Jairo Zuluaga, Matias Chacon, Luis Corrales, Suraj Samtani, Oscar Arrieta, Andres Cardona, Jordi Remon, Claudio Martin.

”Real-world study of first-line nivolumab plus ipilimumab for pleural mesothelioma (ImmunoMeso Latin America) from Diego Enrico et al. In 96 patients, progression-free survival was 8 months, overall survival was 22 months (23 months for epithelioid, 19 months for non-epithelioid). Grade 3-4 adverse events occurred in 18.5% of patients.”

Source: Stephen V Liu/X

Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.